Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Figitumumab with Paclitaxel and Carboplatin in Advanced NSCLC
NCT00147537Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2005
- Primary completion
- Aug 2011
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of figitumumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 2 more. Started Feb 2005; status: completed.
02
Drugs
figitumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00147537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147537.